All together this shows that NOB treatment alone has a greater anti-inflammatory effect on the inhibition of both the TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer than when combined with LPS or CpG-ODN treatment. The gene discussed is TLR9; the disease is prostate cancer.